ClinicalTrials.gg

Program

nacubactam

Also written as “RO7079901”, “co-administration of cefepime and nacubactam” and “co-administration of aztreonam and nacubactam”.

Its studies are mostly in Intraabdominal Infections · Pyelonephritis · Urinary Tract Infections · Gram-Negative Bacterial Infections · Renal Insufficiency, led by 2 companies.

Furthest: phase 3, since Nov 21, 20167 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hoffmann-La Roche40 open or runningphase 1since Nov 21, 2016Nov 21, 2016none ahead
Meiji Seika Pharma30 open or runningphase 3since Mar 2, 2023May 7, 2014none ahead
  • Named in fosun pharma’s own pipeline as OP0595 (beta-lactamase inhibitor), phase 3, as of Sep 21, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 7, 2014First study: phase 1 study in Bacterial InfectionsNew to Meiji Seika PharmaMeiji Seika Pharma · NCT02134834 · 40 enrolled · Australia
  2. Nov 21, 2016Hoffmann-La Roche's first studies: 2 phase 1 studiesNew to Hoffmann-La RocheHoffmann-La Roche · NCT02972255, NCT02975388
  3. May 31, 2017Phase 1 study in Urinary Tract InfectionsHoffmann-La Roche · NCT03174795 · 20 enrolled · United States, Hungary, Latvia and more
  4. Jun 7, 2017Phase 1 study in Gram-Negative Bacterial InfectionsHoffmann-La Roche · NCT03182504 · 21 enrolled · United States
  5. Mar 2, 2023Phase 3 study in Complicated Urinary Tract InfectionMeiji Seika Pharma · NCT05905055 · 126 enrolled · China, Croatia, Czechia and more
  6. Apr 25, 2023Phase 3 study in Complicated Urinary Tract InfectionMeiji Seika Pharma · NCT05887908 · 614 enrolled · Bulgaria, China, Czechia and more

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05887908Complicated Urinary Tract Infection · Bulgaria, China, Czechia and more3CompletedMeiji Seika PharmaNov 22, 2024614
NCT05905055Complicated Urinary Tract Infection · China, Croatia, Czechia and more3CompletedMeiji Seika PharmaSep 1, 2025126
NCT03182504Gram-Negative Bacterial Infections · United States1CompletedHoffmann-La RocheAug 10, 201721
NCT03174795Urinary Tract Infections · United States, Hungary, Latvia and more1CompletedHoffmann-La RocheDec 4, 201720
NCT02975388Renal Insufficiency · United States1CompletedHoffmann-La RocheJul 6, 201729
NCT02972255Healthy Volunteers · United States1CompletedHoffmann-La RocheMar 24, 201746
NCT02134834Bacterial Infections · Australia1CompletedMeiji Seika PharmaAug 201440

How it is read

Names in the registry

  • “RO7079901”, 3 entries
  • “co-administration of cefepime and nacubactam”, 2 entries
  • “co-administration of aztreonam and nacubactam”, 2 entries
  • “nacubactam”, 1 entry
  • “OP0595”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.